Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review

References

• Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD. 2009. Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. Fertil Steril. 91(2):432–439.
   PubMed Web of Science ®Google Scholar
• Al-Inany H, Johnson N. 2006. Drugs for anovulatory infertility in polycystic ovary syndrome. BMJ. 332(7556):1461–1462.
   PubMedGoogle Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. 2006. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 91(11):4237–4245.
   PubMed Web of Science ®Google Scholar
• Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, et al. 2009. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 91(2):456–488.
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A. 2011. Treatment options for polycystic ovary syndrome. Int J Womens Health. 3:25–35.
   PubMedGoogle Scholar
• Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, Stener-Victorin E, Fauser BC, Norman RJ, Teede H. 2016. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 22(6):687–708.
   PubMed Web of Science ®Google Scholar
• Cheang KI, Modi B, Shulleeta M, Evans WS, Pal L, Strauss JF. 2015. Genetic polymorphisms and ovulatory responsiveness to metformin in women with polycystic ovary syndrome. Endocr Rev. 2015:36.
   Google Scholar
• Curry SH, Whelpton R. 2017. Introduction to drug disposition and pharmacokinetics. Chichester, West Sussex: Wiley 3:11–2.
   Google Scholar
• Davis D, Liu X, Segaloff D. 1995. Identification of the sites of N-linked glycosylation on the follicle-stimulating hormone (FSH) receptor and assessment of their role in FSH receptor function. Mol Endocrinol. 9:159–9170.
   PubMedGoogle Scholar
• Deswal R, Yadav A, Dang AS. 2018. Sex hormone binding globulin—an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Syst Biol Reprod Med. 64(1):12–24.
   PubMed Web of Science ®Google Scholar
• Deugarte C, Bartolucci A, Azziz R. 2005. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 83(5):1454–1460.
   PubMed Web of Science ®Google Scholar
• Dolfin E, Guani B, Lussiana C, Mari C, Restagno G, Revelli A. 2011. FSH-receptor Ala307Thr polymorphism is associated to polycystic ovary syndrome and to a higher responsiveness to exogenous FSH in Italian women. J Assist Reprod Genet. 28(10):925–930.
   PubMed Web of Science ®Google Scholar
• Donga E, Dijk MV, Hoogma RPM, Corssmit EPM, Romijn JA. 2013. Insulin resistance in multiple tissues in patients with type 1 diabetes mellitus on long-term continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev. 29(1):33–38.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Chang RJ, Franks S, Legro RS. 2008. Polycystic ovary versus polycystic ovary syndrome. Polycystic Ovary Syndr. 52:401–419.
   Google Scholar
• Evans MB, Hill M. 2015. Hyperandrogenism: acne and hirsutism. In: Shoupe D, editor. Handbook of Gynecology. Springer: Cham.
   Google Scholar
• Gambineri A, Tomassoni F, Gasparini DI, Di Rocco A, Mantovani V, Pagotto U, Altieri P, Sanna S, Fulghesu AM, Pasquali R. 2010. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 95(10):E204–8.
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Glueck CJ. 2008. Is pharmacogenomics our future? Metformin, ovulation and polymorphism of theSTK11gene in polycystic ovary syndrome. Pharmacogenomics. 9(8):1163–1165.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. 2016. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 51(3):417–428.
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Körner A, Stumvoll M, Kovacs P. 2011. TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet. 12:30.
   PubMed Web of Science ®Google Scholar
• Ji M, Kim KR, Lee W, Choe W, Chun S, Min WK. 2016. Genetic polymorphism of CYP2D6 and clomiphene concentrations in infertile patients with ovulatory dysfunction treated with clomiphene citrate. J Korean Med Sci. 31(2):310–314.
   PubMed Web of Science ®Google Scholar
• Khrunin AV, Moisseev A, Gorbunova V, Limborska S. 2010. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 10(1):54–61.
   PubMed Web of Science ®Google Scholar
• Legro RS. 2017. Evaluation and treatment of polycystic ovary syndrome. Endotext. 2000:1–8.
   Google Scholar
• Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, et al. 2008. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab. 93(3):792–800.
   PubMed Web of Science ®Google Scholar
• Leo VD, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. 2016. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 14(1):38.
   PubMedGoogle Scholar
• Lopez-Bermejo A, Diaz M, Moran E, Zegher FD, Ibanez L. 2010. A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. Diabetes Care. 33(7):1544–1548.
   PubMed Web of Science ®Google Scholar
• Maier PS, Mattiello SS, Lages L, Spritzer PM. 2012. 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities. Gynecol Endocrinol. 28(8):606–610.
   PubMed Web of Science ®Google Scholar
• Maier PS, Spritzer PM. 2012. Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. Genet Res Int. 2018:7624932.
   Google Scholar
• Mann R. 2016. Management of female-pattern hair loss. Prescriber. 27(7):17–20.
   Google Scholar
• Moran C, Arriaga M, Rodriguez G, Moran S. 2012. Obesity in polycystic ovary syndrome, polycystic ovary syndrome. In Mukherjee S, editor. Polycystic ovary syndrome. InTech: Mexico; p. 1–17. ISBN: 978-953-51-0094-2.
   Google Scholar
• Mürdter TE, Kerb R, Turpeinen M, Schroth W, Ganchev B, Böhmer GM, Igel S, Schaeffeler E, Zanger U, Brauch H, Schwab M. 2012. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Hum Mol Genet. 21(5):1145–1154.
   PubMed Web of Science ®Google Scholar
• Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. 2004. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update. 10(3):267–280.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. 2016. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14(1):10.
   PubMed Web of Science ®Google Scholar
• Overbeek A, Kuijper EAM, Hendriks ML, Blankenstein MA, Ketel IJG, Twisk JWR, Hompes PGA, Homburg R, Lambalk CB. 2009. Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. Hum Reprod. 24(8):2007–2013.
   PubMed Web of Science ®Google Scholar
• Palomba S, Santagni S, Falbo A, Sala GBL. 2015. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 7:745–763.
   PubMed Web of Science ®Google Scholar
• Pau CT, Cheang KI, Modi BP, Kasippillai T, Keefe CC, Shulleeta M, Evans WS, Pal L, Strauss JF, Nestler JE, Welt CK. 2016. The role of variants regulating metformin transport and action in women with polycystic ovary syndrome. Pharmacogenomics. 17(16):1765–1773.
   PubMed Web of Science ®Google Scholar
• Pedersen AJT, Stage TB, Glintborg D, Andersen M, Christensen MMH. 2018. The pharmacogenetics of metformin in women with polycystic ovary syndrome: a randomized trial. Basic Clin Pharmacol Toxicol. 122(2):239–244.
   PubMed Web of Science ®Google Scholar
• Peigné M, Dewailly D. 2014. Long term complications of polycystic ovary syndrome (PCOS). Ann Endocrinol. 75(4):194–199.
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Ehrmann DA. 2016. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 37(5):467–520.
   PubMed Web of Science ®Google Scholar
• Rosengren A, Perk J, Dallongeville J. 2014. Prevention of cardiovascular disease. The ESC textbook of cardiovascular medicine (2 ed.) Oxford Medicine Online: Chicago, Illinois; p. 467–520.
   Google Scholar
• Schweighofer N, Lerchbaum E, Trummer O, Schwetz V, Pieber T, Obermayer-Pietsch B. 2014. Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. Pharmacogenomics. 15(3):305–317.
   PubMed Web of Science ®Google Scholar
• Teede H, Deeks A, Moran L. 2010. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 30:41.
   Google Scholar
• Tomic V, Tomic J. 2012. Infertility treatment in patients with polycystic ovary syndrome (PCOS). J Fertiliz in Vitro. 02(02):e113.
   Google Scholar
• Turner RM, Park BK, Pirmohamed M. 2015. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wires Syst Biol Med. 7(4):221–241.
   PubMed Web of Science ®Google Scholar
• Valkenburg O, van Santbrink EJP, König TE, Themmen APN, Uitterlinden AG, Fauser BCJM, Lambalk CB, Laven JSE. 2015. Follicle-stimulating hormone receptor polymorphism affects the outcome of ovulation induction in normogonadotropic (World Health Organization class 2) anovulatory subfertility. Fertil Steril. 103(4):1081–1088e3.
   PubMed Web of Science ®Google Scholar
• Velazquez E, Mendoza S, Hamer T, Sosa F, Glueck C. 1994. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp. 43(5):647–654.
   PubMed Web of Science ®Google Scholar
• Wakisaka N, Taira Y-I, Ishikawa M, Nakamizo Y, Kobayashi K, Uwabu M, Fukuda Y, Taguchi Y, Hama T, Kawakami M. 2005. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc. 10(3):293–294.
   PubMedGoogle Scholar
• Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 2002. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 302(2):510–515.
   PubMed Web of Science ®Google Scholar
• Williams CE, Creighton SM. 2012. Menstrual disorders in adolescents: review of current practice. Horm Res Paediatr. 78(3):135–143.
   PubMed Web of Science ®Google Scholar